Protocol No.: F8394-201

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Principal Investigator
Aulakh, Sonikpreet
Phase
II
Age Group
Adult
Applicable Disease Site
Brain Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Nina Moore, RN
Research Specialist
Phone: +1 304-293-2991

View on ClinicalTrials.gov